Effect of melatonin on insomnia and daytime sleepiness, in patients with obstructive sleep apnea and insomnia (COMISA): A randomized double-blinded placebo-controlled trial
Authors:
Open Access
- 30 May 2024
- journal article
- research article
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 10 (1) , 1-12
Abstract
Background: COMISA is a common disorder that results in nighttime awakenings ,daytime sleepiness and PAP intolerance. Cognitive behavioral therapy for insomnia is used to improve PAP adherence and no medication has been evaluated in such population yet. Melatonin with its chronobiotic and antioxidant effects may have potential benefits on COMISA consequences at the appropriate dose and time. This study aimed to evaluate the effect of melatonin on sleep quality, daytime sleepiness and PAP Compliance in patients with COMISA. Methods: This double-blind placebo trial randomly assigned eligible OSA patients who suffered from insomnia despite using PAP for over a month to receive either melatonin 10 mg or placebo. The primary outcomes were measured by changes in the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), and Functional Outcomes of Sleep Questionnaire (FOSQ-10) over one month. Adherence to PAP was measured by the results of the PAP device reports on the average length of time and number of nights that the device was used. Results: Thirty patients were enrolled in the study after randomization. The melatonin arm showed significant improvement in all four primary outcomes compared to the placebo arm. The PSQI score was 3.836±1.839 in the melatonin arm versus 10.522±3.626 in the placebo arm (PvaluePvaluePvaluePvalue= 0.006). Additionally, nighttime consequences such as sleep latency and awakenings showed significant improvement in the melatonin arm. PAP devices results revealed improvement in duration of PAP use overnight. Conclusions: Administering melatonin has been shown to improve self-reported sleep quality and PAP adherence in patients with COMISA. Trial registration: Registration number IRCT20220105053635N1 was issued by the Iranian Registry of Clinical Trials (IRCT).Keywords
This publication has 42 references indexed in Scilit:
- Trazodone Effects on Obstructive Sleep Apnea and Non-REM Arousal ThresholdAnnals of the American Thoracic Society, 2015
- Medication Effects on Sleep and BreathingClinics in Chest Medicine, 2014
- Evaluation of Exogenous Melatonin Administration in Improvement of Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease2013
- Validity and reliability of the Iranian version of the insomnia severity index.2012
- The Epworth Sleepiness Scale: translation and validation study of the Iranian versionSleep and Breathing, 2012
- Reliability and validity of the Persian version of the Pittsburgh Sleep Quality Index (PSQI-P)Sleep and Breathing, 2011
- Effectiveness of Ramelteon for Insomnia Symptoms in Older Adults with Obstructive Sleep Apnea: A Randomized Placebo-Controlled Pilot StudyJournal of Clinical Sleep Medicine, 2010
- Comorbid insomnia and obstructive sleep apnea: challenges for clinical practice and research.2010
- Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAPEuropean Respiratory Journal, 2007
- Melatonin Improves Sleep in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2004